Parkinson’s Disease Therapeutics Market: Treatment Type (Medication and Surgical Therapy (Deep Brain Stimulation (DBS) and Carbidopa/Levodopa Enteral Suspension), End-User (Hospitals & Clinics, Academic & Industrial Research) - Forecast Till 2027
ID: MRFR/Pharma/1043-HCR | February 2021 | Region: Global | 90 pages
Market Scenario
Globally the Parkinson’s disease therapeutics market is increasing rapidly. The major factor that drives the growth of the Parkinson’s disease therapeutics market is the increasing growth in aging population. Furthermore, increasing environmental factors & genetic heredity is increasing the growth of the Parkinson’s disease therapeutics market. Moreover, the risk of Parkinson’s disease increases with age, and the disease mainly affects a person over 50 years of age. The treatments for the Parkinson’s disease are mainly symptomatic and no curative treatment options.
However, expiration of patent drugs is expected to hamper the Parkinson’s disease therapeutics market growth during the forecast period.
Research Methodology
Market Research Future research is conducted by industry experts who offer insights into industry structure, market segmentation, assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.
- Primary Research
Extensive primary research was conducted to gain a deeper insight into the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.
- Secondary Research
Secondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and commercial study of the global Parkinson’s disease therapeutics market. It was also used to obtain key information about major players, market classification, and segmentation according to industry trends, geographical markets, and developments related to the market and perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, international organization of chemical manufacturers, some paid databases, and many others.
Parkinson’s disease Therapeutics Market, by Key Players
- Salix Pharmaceuticals
- GlaxoSmithKline Plc
- Impax Laboratories, LLC
- Teva Pharmaceutical Industries Ltd
- Novartis AG, Orion Corporation
- Mylan N.V.
- Par Pharmaceutical
- Cipla Inc.
- Daiichi Sankyo
- Apotex Inc.
- Wockhardt Limited
Segmentation
The Parkinson’s disease therapeutics market is segmented on the basis of treatment type and end-user. The Parkinson’s disease therapeutics market by treatment type is segmented into medication and surgical therapy. Medication segment is segmented further into dopamine precursors, peripheral decarboxylase inhibitors, COMT inhibitors, MAO inhibitors, and others. Surgery therapy is further segmented into deep brain stimulation (DBS) and carbidopa/levodopa enteral suspension.
On the basis of end-user, the Parkinson’s disease therapeutics market is categorized into hospitals & clinics, academic & industrial research, and others.
On the basis of region, the global Parkinson’s disease therapeutics market is segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas is sub-segmented into North America and South America. The North American region is further segmented into the U.S. and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the U.K., Spain, and the rest of Western Europe. The Asia Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
Regional Market Summary
Parkinson’s Disease Therapeutics Market Share (%), by Region, 2017
Sources: National Electronic Health Records Survey, U.S. Department of Health & Human Services, National Center for Health Statistics
The Parkinson’s disease therapeutics market is dominated by North America owing to the rising healthcare expenditure that contributes to enhancing the market growth in this region. According to Parkinson Association of the Carolinas, approximately 60,000 Americans are diagnosed with Parkinson’s disease each year.
It is estimated that Europe stood second in the global Parkinson’s disease therapeutics market. Rising government initiatives to promote the healthcare sector and increased adoption of research and development activities for chronic diseases in the healthcare domain drive the market in this region. Moreover, the entry of market leaders into strategic partnerships and collaborations with the chemical industry contribute to the growth of the Parkinson’s disease therapeutics market in Europe.
Asia Pacific is likely to witness growth in the Parkinson’s disease therapeutics market during the forecast period owing to the increasing number of healthcare organizations, increasing prevalence of Parkinson’s disease. Moreover, increasing prevalence of geriatric population in the region influence the Parkinson’s disease therapeutics market growth. China, India, and Japan are the key market players in this region, and Asia Pacific is expected to be the fastest growing market for the Parkinson’s disease therapeutics.
The Middle East and Africa holds the least share in the global Parkinson’s disease therapeutics market due to the presence of stringent government policies and poor economies.
Market Segmentation and Key Market Players
Parkinson’s disease Therapeutics Market, by Treatment Type
- Medications
- Dopamine Precursors
- Peripheral Decarboxylase Inhibitors
- COMT Inhibitors
- MAO Inhibitors
- Others
- Surgical Therapy
- Deep Brain Stimulation (DBS)
- Carbidopa/Levodopa Enteral Suspension
Parkinson’s disease Therapeutics Market, by End-user
- Hospitals & Clinics
- Academic & Industrial Research
- Others
Parkinson’s disease Therapeutics Market, by Region
- The Americas
- Europe
- Asia Pacific
- The Middle East & Africa
Intended Audience
- Contract Research Organizations (CROs)
- Academic Medical Institutes and Universities
- Government and private laboratories
- Research and Development (R&D) companies
- Market research and consulting service providers
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size | 2027: Significant Value |
| CAGR | 2020-2027: Substantial CAGR |
| Base Year | 2019 |
| Forecast Period | 20202-2027 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Treatment Type, End User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Salix Pharmaceuticals, GlaxoSmithKline Plc, Impax Laboratories, LLC, Teva Pharmaceutical Industries Ltd, Novartis AG, Orion Corporation, Mylan N.V., Par Pharmaceutical, Cipla Inc., Daiichi Sankyo, Apotex Inc., Wockhardt Limited |
| Key Market Opportunities | New product launches and R&D Amongst major key Players |
| Key Market Drivers |
|
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Parkinson’s disease Therapeutics Market, by Treatment Type
6.1 Introduction
6.2 Medications
6.2.1 Dopamine Precursors
6.2.2 Peripheral Decarboxylase Inhibitors
6.2.3 COMT Inhibitors
6.2.4 MAO Inhibitors
6.2.5 Others
6.3 Surgical Therapy
6.3.1 Deep Brain Stimulation (DBS)
6.3.2 Carbidopa/Levodopa Enteral Suspension
Chapter 7. Global Parkinson’s disease Therapeutics Market, by End-User
7.1 Introduction
7.2 Hospitals & Clinics
7.3 Academic & Industrial Research
7.4 Others
Chapter 8. Global Parkinson’s disease Therapeutics Market, by Region
8.1 Introduction
8.2 America
8.2.1 North America
8.2.1.1 U.S.
8.2.1.2 Canada
8.2.2 South America
8.3 Europe
8.3.1 Western Europe
8.3.1.1 Germany
8.3.1.2 France
8.3.1.3 Italy
8.3.1.4 Spain
8.3.1.5 U.K.
8.3.1.6 Rest of Western Europe
8.3.2 Eastern Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 Republic of Korea
8.4.6 Rest of Asia Pacific
8.5 The Middle East & Africa
8.5.1 United Arab Emirates
8.5.2 Saudi Arabia
8.5.3 Oman
8.5.4 Kuwait
8.5.5 Qatar
8.5.6 Rest of the Middle East & Africa
Chapter 9. Company Landscape
9.1 Introduction
9.2 Market Share Analysis
9.3 Key Development & Strategies
9.3.1 Key Developments
Chapter 10 Company Profiles
10.1 Salix Pharmaceuticals
10.1.1 Company Overview
10.1.2 Type Overview
10.1.3 Financials
10.2.4 Key Developments
10.1.5 SWOT Analysis
10.2 GlaxoSmithKline Plc
10.2.1 Company Overview
10.2.2 Type Overview
10.2.3 Financial Overview
10.2.4 Key Developments
10.2.5 SWOT Analysis
10.3 Impax Laboratories, LLC
10.3.1 Company Overview
10.3.2 Type Overview
10.3.3 Financial Overview
10.3.4 Key Development
10.3.5 SWOT Analysis
10.4 Teva Pharmaceutical Industries Ltd
10.4.1 Company Overview
10.4.2 Type/Business Segment Overview
10.4.3 Financial Overview
10.4.4 Key Development
10.4.5 SWOT Analysis
10.5 Novartis AG
10.5.1 Company Overview
10.5.2 Type Overview
10.5.3 Financial overview
10.5.4 Key Developments
10.5.5 SWOT Analysis
10.6 Orion Corporation
10.6.1 Company Overview
10.6.2 Type Overview
10.6.3 Financial Overview
10.6.4 Key Developments
10.6.5 SWOT Analysis
10.7 Mylan N.V.
10.7.1 Overview
10.7.2 Type Overview
10.7.3 Financials
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.8 Par Pharmaceutical
10.8.1 Overview
10.8.2 Type Overview
10.8.3 Financials
10.8.4 Key Developments
10.8.5 SWOT Analysis
10.9 Cipla Inc.
10.9.1 Overview
10.9.2 Type Overview
10.9.3 Financials
10.9.4 Key Developments
10.9.5 SWOT Analysis
10.10 Daiichi Sankyo
10.10.1 Overview
10.10.2 Type Overview
10.10.3 Financials
10.10.4 Key Developments
10.10.5 SWOT Analysis
10.11 Apotex Inc.
10.11.1 Overview
10.11.2 Type Overview
10.11.3 Financials
10.11.4 Key Developments
10.11.5 SWOT Analysis
10.12 Wockhardt Limited
10.12.1 Overview
10.12.2 Type Overview
10.12.3 Financials
10.12.4 Key Developments
10.12.5 SWOT Analysis
10.13 ACADIA Pharmaceuticals Inc
10.13.1 Overview
10.13.2 Type Overview
10.13.3 Financials
10.13.4 Key Developments
10.13.5 SWOT Analysis
10.14 Abbott
10.14.1 Overview
10.14.2 Type Overview
10.14.3 Financials
10.14.4 Key Developments
10.14.5 SWOT Analysis
10.15 Others
Chapter 11 Appendix
LIST OF TABLES
Table 1 Global Parkinson’s disease Therapeutics Market Industry Synopsis, 2020-2027
Table 2 Global Parkinson’s disease Therapeutics Market Estimates & Forecast, 2020-2027, (USD Million)
Table 3 Global Parkinson’s disease Therapeutics Market, by Region, 2020-2027, (USD Million)
Table 4 Global Parkinson’s disease Therapeutics Market, by Treatment Type, 2020-2027, (USD Million)
Table 6 Global Parkinson’s disease Therapeutics Market, by End-User, 2020-2027, (USD Million)
Table 7 North America Parkinson’s disease Therapeutics Market, by Treatment Type, 2020-2027, (USD Million)
Table 9 North America Parkinson’s disease Therapeutics Market, by End-User, 2020-2027, (USD Million)
Table 10 U.S. Parkinson’s disease Therapeutics Market, by Treatment Type, 2020-2027, (USD Million)
Table 11 U.S. Parkinson’s disease Therapeutics Market, by End-User, 2020-2027, (USD Million)
Table 12 Canada Parkinson’s disease Therapeutics Market, by Treatment Type, 2020-2027, (USD Million)
Table 13 Canada Parkinson’s disease Therapeutics Market, by End-User, 2020-2027, (USD Million)
Table 14 South America Parkinson’s disease Therapeutics Market, by Treatment Type, 2020-2027, (USD Million)
Table 15 South America Parkinson’s disease Therapeutics Market, by End-User, 2020-2027, (USD Million)
Table 16 Europe Parkinson’s disease Therapeutics Market, by Treatment Type, 2020-2027, (USD Million)
Table 17 Europe Parkinson’s disease Therapeutics Market, by End-User, 2020-2027, (USD Million)
Table 18 Western Europe Parkinson’s disease Therapeutics Market, by Treatment Type, 2020-2027, (USD Million)
Table 19 Western Europe Parkinson’s disease Therapeutics Market, by End-User, 2020-2027, (USD Million)
Table 20 Eastern Europe Parkinson’s disease Therapeutics Market, by Treatment Type, 2020-2027, (USD Million)
Table 21 Eastern Europe Parkinson’s disease Therapeutics Market, by End-User, 2020-2027, (USD Million)
Table 22 Asia Pacific Parkinson’s disease Therapeutics Market, by Treatment Type, 2020-2027, (USD Million)
Table 23 Asia Pacific Parkinson’s disease Therapeutics Market, by End-User, 2020-2027, (USD Million)
Table 24 The Middle East & Africa Parkinson’s disease Therapeutics Market, by Treatment Type, 2020-2027, (USD Million)
Table 25 The Middle East & Africa Parkinson’s disease Therapeutics Market, by End-User, 2020-2027, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Parkinson’s disease Therapeutics Market
Figure 3 Market Dynamics for Global Parkinson’s disease Therapeutics Market
Figure 4 Global Parkinson’s disease Therapeutics Market Share, by Treatment Type, 2020
Figure 5 Global Parkinson’s disease Therapeutics Market Share, by End-User, 2020
Figure 6 Global Parkinson’s disease Therapeutics Market Share, by Region, 2020
Figure 7 North America Parkinson’s disease Therapeutics Market Share, by Country, 2020
Figure 8 Europe Parkinson’s disease Therapeutics Share, by Country, 2020
Figure 9 Asia Pacific Parkinson’s disease Therapeutics Market Share, by Country, 2020
Figure 10 The Middle East & Africa Parkinson’s disease Therapeutics Market Share, by Country, 2020
Figure 11 Global Parkinson’s disease Therapeutics Market: Company Share Analysis, 2020 (%)
Figure 12 Abbott: Key Financials
Figure 13 Abbott: Segmental Revenue
Figure 14 Abbott: Geographical Revenue
Figure 15 Salix Pharmaceuticals: Key Financials
Figure 16 Salix Pharmaceuticals: Segmental Revenue
Figure 17 Salix Pharmaceuticals: Geographical Revenue
Figure 18 GlaxoSmithKline Plc: Key Financials
Figure 19 GlaxoSmithKline Plc: Segmental Revenue
Figure 20 GlaxoSmithKline Plc: Geographical Revenue
Figure 21 Impax Laboratories, LLC: Key Financials
Figure 22 Impax Laboratories, LLC: Segmental Revenue
Figure 23 Impax Laboratories, LLC: Geographical Revenue
Figure 24 Teva Pharmaceutical Industries Ltd: Key Financials
Figure 25 Teva Pharmaceutical Industries Ltd: Segmental Revenue
Figure 26 Teva Pharmaceutical Industries Ltd: Geographical Revenue
Figure 27 Novartis AG: Key Financials
Figure 28 Novartis AG: Segmental Revenue
Figure 29 Novartis AG: Geographical Revenue
Figure 30 Orion Corporation: Key Financials
Figure 31 Orion Corporation: Segmental Revenue
Figure 32 Orion Corporation: Geographical Revenue
Figure 33 Mylan N.V.: Key Financials
Figure 34 Mylan N.V.: Segmental Revenue
Figure 35 Mylan N.V.: Geographical Revenue
Figure 36 Par Pharmaceutical: Key Financials
Figure 37 Par Pharmaceutical: Segmental Revenue
Figure 38 Par Pharmaceutical: Geographical Revenue
Figure 39 Cipla Inc.: Key Financials
Figure 40 Cipla Inc.: Segmental Revenue
Figure 41 Cipla Inc.: Geographical Revenue
Figure 42 Daiichi Sankyo: Key Financials
Figure 43 Daiichi Sankyo: Segmental Revenue
Figure 44 Daiichi Sankyo: Geographical Revenue
Figure 45 Apotex Inc.: Key Financials
Figure 46 Apotex Inc.: Segmental Revenue
Figure 47 Apotex Inc.: Geographical Revenue